Clinical significance of CYP2C9-status guided valproic acid therapy in children

Epilepsia

Volumn 56, Issue 6, 2015, Pages 849-855

  Búdi, Tamás ^a   Tõth, Katalin ^b   Nagy, Andrea ^c   Szever, Zsuzsa ^c   Kiss, Ádám ^b   Temesvári, Manna ^b   Háfra, Edit ^b   Garami, Miklõs ^a   Tapodi, Adrienn ^c   Monostory, Katalin ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c HEIM PÁL CHILDREN S HOSPITAL   (Hungary)

Author keywords

Anticonvulsant therapy; CYP2C9 expression; CYP2C9 genotype; Cytochrome P450; Personalized pharmacotherapy

Indexed keywords

ALKALINE PHOSPHATASE; CYTOCHROME P450 2C9; VALPROIC ACID; ANTICONVULSIVE AGENT;

ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLELE; ANTICONVULSANT THERAPY; ARTICLE; ASSAY; BEHAVIOR DISORDER; BLOOD CELL COUNT; CHILD; CHILDHOOD DISEASE; CLINICAL PRACTICE; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; ENURESIS; ENZYME ACTIVITY; FATIGUE; FEMALE; GENOTYPE; HAIR LOSS; HUMAN; HYPERAMMONEMIA; INFANT; LEUKOCYTE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SCREENING; SIDE EFFECT; SOMNOLENCE; TONIC CLONIC SEIZURE; WEIGHT CHANGE; WEIGHT GAIN; ADVERSE DRUG REACTION; BLOOD; EPILEPSY; GENETICS; PHARMACOGENETICS; PRESCHOOL CHILD;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2C9; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPILEPSY; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; PHARMACOGENETICS; VALPROIC ACID;

EID: 84930473495     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13011     Document Type: Article

References (33)

1. Nanau RM, Neuman MG,. Adverse drug reactions induced by valproic acid. Clin Biochem 2013; 46: 1323-1338.
2. Dreifuss FE, Langer DH,. Hepatic considerations in the use of antiepileptic drugs. Epilepsia 1987; 28 (Suppl. 2): S23-S29.
3. Bryant AE, Dreifuss FE,. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46: 465-469.
4. Abbott FS, Anari MR,. Chemistry and biotransformation. In, Loscher W, (Ed) Milestones in drug therapy, valproate. Basel: Birkhauser Verlag, 1999: 47-75.
5. Ho PC, Abbott FS, Zanger UM, et al., Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 2003; 3: 335-342.
6. Kiang TK, Ho PC, Anari MR, et al., Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C91/1 genotype. Toxicol Sci 2006; 94: 261-271.
7. Siemes H, Nau H, Schultze K, et al., Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia 1993; 34: 332-346.
8. Strassburg CP, Vogel A, Kneip S, et al., Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002; 50: 259-265.
9. Reith DM, Andrews J, Parker-Scott S, et al., Urinary excretion of valproate metabolites in children and adolescents. Biopharm Drug Dispos 2000; 21: 327-330.
10. Ponchaut S, van Hoof F, Veitch K,. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. Biochem Pharmacol 1992; 43: 644-647.
11. Silva MF, Aires CC, Luis PB, et al., Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 2008; 31: 205-216.
12. Stewart CF, Hampton EM,. Effect of maturation on drug disposition in pediatric patients. Clin Pharm 1987; 6: 548-564.
13. Ginsberg G, Hattis D, Sonawane B, et al., Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002; 66: 185-200.
14. Zaccara G, Messori A, Moroni F,. Clinical pharmacokinetics of valproic acid-1988. Clin Pharmacokinet 1988; 15: 367-389.
15. Zhou SF, Zhou ZW, Huang M,. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2010; 278: 165-188.
16. Shah RR, Smith RL,. Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol 2015; 79: 222-240.
17. Temesvári M, Kõbori L, Paulik J, et al., Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther 2012; 341: 294-305.
18. Tõth K, Búdi T, Kiss Á, et al., Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy. Pers Med 2015; 12: 201-209.
19. Guerrini R,. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs 2006; 8: 113-129.
20. Shaw JL, Cohen A, Konforte D, et al., Validity of establishing pediatric reference intervals based on hospital patient data: a comparison of the modified Hoffmann approach to CALIPER reference intervals obtained in healthy children. Clin Biochem 2014; 47: 166-172.
21. Anderson GD,. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002; 43 (Suppl. 3): 53-59.
22. Fisher E, Siemes H, Pund R, et al., Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity. Epilepsia 1992; 33: 165-171.
23. Kochen W, Schneider A, Ritz A,. Abnormal metabolism of valproic acid in fatal hepatic failure. Eur J Pediatr 1983; 141: 30-35.
24. Tan L, Yu JT, Sun YP, et al., The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 2010; 112: 320-323.
25. Guo Y, Hu C, He X, et al., Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokinet 2012; 27: 536-542.
26. Kirchheiner J, Tsahuridu M, Jabrane W, et al., The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Pers Med 2004; 1: 63-84.
27. Zhou SF, Liu JP, Chowbay B,. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41: 89-295.
28. Zanger UM, Schwab M,. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141.
29. Yu N, Di Q, Hu Y, et al., A meta-analysis of pro-inflammatory cytokines in the plasma of epileptic patients with recent seizure. Neurosci Lett 2012; 514: 110-115.
30. Czekaj P, Skowronek R,. Transcription factors potentially involved in regulation of cytochrome P450 gene expression. In, Paxton J, (Ed) Topics on drug metabolism. Rijeka Croatia: InTech Europe, 2012: 171-190.
31. Guo CY, Ronen GM, Atkinson SA,. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001; 42: 1141-1147.
32. Aires CC, van Cruchten A, Ijlst L, et al., New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol 2011; 55: 426-434.
33. Tseng YL, Huang CR, Lin CH, et al., Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. Medicine 2014; 93: e66.